Halozyme Therapeutics (LTS:0J2O) Other Net Income (Loss) : $0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics Other Net Income (Loss)?

Halozyme Therapeutics's Other Net Income (Loss) for the three months ended in Mar. 2024 was $-0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.

Halozyme Therapeutics's quarterly Other Net Income (Loss) increased from Sep. 2023 ($0.0 Mil) to Dec. 2023 ($0.0 Mil) but then declined from Dec. 2023 ($0.0 Mil) to Mar. 2024 ($-0.0 Mil).

Halozyme Therapeutics's annual Other Net Income (Loss) increased from Dec. 2021 ($-0.0 Mil) to Dec. 2022 ($-0.0 Mil) and increased from Dec. 2022 ($-0.0 Mil) to Dec. 2023 ($0.0 Mil).

Halozyme Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Halozyme Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Other Net Income (Loss) Chart

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Halozyme Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Halozyme Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Halozyme Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (LTS:0J2O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

HALO:USA RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (LTS:0J2O) Headlines

No Headlines